Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Reduced Margin Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancers.Cureus.  12:e8618. 2020
2019 Electromagnetic Transponder Based Tracking and Gating in the Radiotherapeutic Treatment of Thoracic MalignanciesPractical Radiation Oncology.  9:456-464. 2019
2019 Dose perturbation and inhomogeneity of multi-arrays of 125I seed-loaded stent for treatment of portal vein tumor thrombosis 2019
2019 Stereotactic radiosurgery with MLC-defined arcs: Verification of dosimetry, spatial accuracy, and end-to-end testsJournal of Applied Clinical Medical Physics.  20:84-98. 2019
2018 Dynamics of the vaginal wall dose in HDR interstitial brachytherapy for gynecological cancer: Systematic analysis of phantom vs patient caseMedical Dosimetry.  43:237-242. 2018
2016 A novel phantom and procedure providing submillimeter accuracy in daily QA tests of accelerators used for stereotactic radiosurgeryJournal of Applied Clinical Medical Physics.  17:246-253. 2016
2016 A novel phantom and procedure providing submillimeter accuracy in daily QA tests of accelerators used for stereotactic radiosurgeryJournal of Applied Clinical Medical Physics.  17:246-253. 2016
2014 End-to-end test of spatial accuracy in Gamma Knife treatments for trigeminal neuralgiaMedical Physics.  41. 2014
2014 Image-guided brachytherapy for cervical cancer: Analysis of D2 cc hot spot in three-dimensional and anatomic factors affecting D2 cc hot spot inorgans at riskBrachytherapy.  13:203-209. 2014
2014 Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patientsCancer Biotherapy and Radiopharmaceuticals.  29:12-17. 2014
2014 A technique using 99mTc-mebrofenin SPECT for radiotherapy treatment planning for liver cancers or metastasesMedical Dosimetry.  39:7-11. 2014
2014 Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumabJournal of Nuclear Medicine.  55:1636-1642. 2014
2013 Phase i study of a modified regimen of 90yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed cd20+ non-hodgkin lymphomaCancer Biotherapy and Radiopharmaceuticals.  28:370-379. 2013
2013 Intraoperative ultrasound guidance during intracavitary brachytherapy applicator placement in cervical cancer; The university of alabama at birmingham experienceInternational Journal of Gynecological Cancer.  23:559-566. 2013
2012 Image-based 3D treatment planning for vaginal cylinder brachytherapy: Dosimetric effects of bladder filling on organs at risk 2012
2012 SU‐E‐T‐434: Use of Deformable Registration for Cumulated Dose Calculation in Image‐Guided Intracavitary Bracytherapy for Cervical CancerMedical Physics.  39:3804. 2012
2011 Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaCancer Biotherapy and Radiopharmaceuticals.  26:127-133. 2011
2010 The use of endoscopic ultrasound-guided gold markers in image-guided radiation therapy of pancreatic cancers: A case seriesEndoscopy.  42:423-425. 2010
2010 Effects of Bladder Distension on Organs at Risk in 3D Image-Based Planning of Intracavitary Brachytherapy for Cervical Cancer 2010
2010 Impact of rituximab treatment on 90Y-ibritumomab dosimetry for patients with non-Hodgkin lymphomaJournal of Nuclear Medicine.  51:150-157. 2010
2009 Development of an accelerated GVF semi-automatic contouring algorithm for radiotherapy treatment planningComputers in Biology and Medicine.  39:650-656. 2009
2009 Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source.Journal of Applied Clinical Medical Physics.  10:2903. 2009
2009 Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma.Journal of Clinical Oncology.  27:e13006. 2009
2009 MIRD dose estimate report No. 20: Radiation aBsorbed-dose estimates for 111In-And 90Y-ibritumomab TiuxetanJournal of Nuclear Medicine.  50:644-652. 2009
2009 Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR sourceJournal of Applied Clinical Medical Physics.  10:90-102. 2009
2009 Performance of a commercial macro Monte Carlo dose calculation algorithm for determining output factors of clinical electron fieldsTechnology in Cancer Research and Treatment.  8:307-314. 2009
2008 Conventional High-Dose-Rate Brachytherapy With Concomitant Complementary IMRT Boost: A Novel Approach for Improving Cervical Tumor Dose Coverage 2008
2008 A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebraeJournal of Nuclear Medicine.  49:279-284. 2008
2007 Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma 2007
2007 Image-based three-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: Dose-volume histograms of the bladder, rectum, sigmoid colon, and small bowelBrachytherapy.  6:187-194. 2007
2007 Intensity modulation with respiratory gating for radiotherapy of the pleural spaceMedical Dosimetry.  32:16-22. 2007
2007 SU‐FF‐J‐78: 3‐D Target Localization at the End of Expiration Prior to Respiration‐Gated Radiotherapy TreatmentMedical Physics.  34:2386. 2007
2007 SU‐FF‐T‐372: Registration of Frameless High‐Field MRI to Low‐Field Frame‐Based MRI Images in Leksell Gamma‐Knife (LGK) RadiosurgeryMedical Physics.  34:2487. 2007
2007 TH‐C‐AUD‐03: Impact of Respiratory Motion On Helical Tomotherapy Dose Delivery: A Phantom Study with 3‐D Volumetric Dose MeasurementsMedical Physics.  34:2626-2627. 2007
2006 Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer 2006
2006 Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy 2006
2006 Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade gliomaJournal of Clinical Oncology.  24:3644-3650. 2006
2006 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapyJournal of Nuclear Medicine.  47:534-542. 2006
2006 Comprehensive evaluation of a commercial macro Monte Carlo electron dose calculation implementation using a standard verification data setMedical Physics.  33:1540-1551. 2006
2006 Dosimetric and radiobiological impact of dose fractionation on respiratory motion induced IMRT delivery errors: A volumetric dose measurement studyMedical Physics.  33:1380-1387. 2006
2005 Imaging glioma extent with 131I-TM-601Journal of Nuclear Medicine.  46:580-586. 2005
2005 Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesJournal of Nuclear Medicine.  46:642-651. 2005
2005 Determination of field size-dependent wedge factors from a few selected measurementsJournal of Applied Clinical Medical Physics.  6:51-60. 2005
2005 Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513))Cancer Biotherapy and Radiopharmaceuticals.  20:671. 2005
2005 Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetryJournal of Nuclear Medicine.  46:1034-1041. 2005
2005 Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibodyCancer Biotherapy and Radiopharmaceuticals.  20:662-670. 2005
2005 Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 regionCancer Biotherapy and Radiopharmaceuticals.  20:502-513. 2005
2005 Phase I study of90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administrationCancer Biotherapy and Radiopharmaceuticals.  20:467-478. 2005
2005 Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion proteinCancer Biotherapy and Radiopharmaceuticals.  20:379-390. 2005
2005 High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyClinical Cancer Research.  11:5920-5927. 2005
2005 Clinically useful marrow dosimetry for targeted radionuclide therapyCancer Biotherapy and Radiopharmaceuticals.  20:119-122. 2005
2005 Testicular uptake and radiation dose in patients receiving Zevalin™ and Pretarget™ CC49Fusion proteinCancer Biotherapy and Radiopharmaceuticals.  20:110-118. 2005
2005 Determination of field size-dependent wedge factors from a few selected measurements.Journal of Applied Clinical Medical Physics.  6:51-60. 2005
2005 MO‐D‐I‐609‐07: Combined Scatter Subtraction and Digital Restoration of Ho‐166 Images for QuantificationMedical Physics.  32:2054. 2005
2005 Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing miceJournal of Neuro-Oncology.  71:113-119. 2005
2005 SU‐EE‐A1‐04: Integrated Complementary IMRT Combined with Image‐Guided HDR Brachytherapy for Cancers of the Uterine CervixMedical Physics.  32:1902. 2005
2005 SU‐FF‐J‐123: Residual Tumor Motion in Respiratory Gated CT Treatment PlaningMedical Physics.  32:1948. 2005
2004 ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomasClinical Cancer Research.  10:7555-7565. 2004
2004 A dynamic supraclavicular field-matching technique for head-and-neck cancer patients treated with IMRT 2004
2004 Dose errors due to inhomogeneities in balloon catheter brachytherapy for breast cancer 2004
2004 Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer 2004
2004 Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaBlood.  104:227-236. 2004
2004 Attenuation of intracavitary applicators in 192Ir-HDR brachytherapyMedical Physics.  31:2097-2106. 2004
2003 Custom step wedge blocking using dynamic multileaf collimation for parametrial pelvic boost irradiation following brachytherapy for carcinoma of the cervixMedical Physics.  30:2699-2702. 2003
2003 Dosimetric effect of respiration-gated beam on IMRT deliveryMedical Physics.  30:2241-2252. 2003
2003 A Novel Monoclonal Antibody Design for RadioimmunotherapyCancer Biotherapy and Radiopharmaceuticals.  18:751-759. 2003
2003 Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapyCancer Biotherapy and Radiopharmaceuticals.  18:393-404. 2003
2003 Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapyCancer Biotherapy and Radiopharmaceuticals.  18:209-215. 2003
2003 Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbsCancer Biotherapy and Radiopharmaceuticals.  18:231-237. 2003
2003 Validation of target volume and position in respiratory gated CT planning and treatmentMedical Physics.  30:3196-3205. 2003
2002 Assaying 192Ir line sources using a standard length well chamberMedical Physics.  29:2692-2697. 2002
2002 Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapyJournal of Nuclear Medicine.  43:1245-1253. 2002
2002 Model prediction of treatment planning for dose-fractionated radioimmunotherapy.Cancer.  94:1264-1269. 2002
2002 A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancerClinical Cancer Research.  8:2806-2811. 2002
2002 Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. 2002
2001 Metabolite production in patients with lymphoma after radiometal-labeled antibody administrationJournal of Nuclear Medicine.  42:1324-1333. 2001
2001 Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for metastatic prostate cancerClinical Cancer Research.  7:1561-1568. 2001
2000 A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma 2000
2000 A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. 2000
2000 Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphomaJournal of Nuclear Medicine.  41:952-958. 2000
2000 Are Radiometal-Labeled Antibodies Better Than Iodine-131-Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67-, Iodine-131-, and Yttrium-90-Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma 2000
1999 A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for Non-Hodgkin's lymphomaJournal of Nuclear Medicine.  40:2014-2020. 1999
1999 Practical determination of patient-specific marrow dose using radioactivity concentration in blood and bodyJournal of Nuclear Medicine.  40:2102-2106. 1999
1999 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.Clinical Cancer Research.  5:3330s-3336s. 1999
1999 Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.Clinical Cancer Research.  5:3243s-3248s. 1999
1999 Strategies for developing effective radioimmunotherapy for solid tumors.Clinical Cancer Research.  5:3219s-3223s. 1999
1999 Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patientsNuclear Medicine and Biology.  26:841-845. 1999
1999 Factors affecting 131I-Lym-1 pharmacokinetics and radiationdosimetry in patients with non-Hodgkin's lymphoma and chroniclymphocytic leukemiaJournal of Nuclear Medicine.  40:1317-1326. 1999
1999 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.Clinical Cancer Research.  5:533-541. 1999
1999 67Cu- versus 131I-labeled Lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphomaClinical Cancer Research.  5:533-541. 1999
1999 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.Journal of Nuclear Medicine.  40:302-310. 1999
1999 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaJournal of Nuclear Medicine.  40:302-310. 1999
1999 Dosimetry for radioimmunotherapy: A rapidly evolving field - EditorialCancer Biotherapy and Radiopharmaceuticals.  14:67-70. 1999
1999 Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphomaCancer Biotherapy and Radiopharmaceuticals.  14:167-176. 1999
1999 Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storageCancer Biotherapy and Radiopharmaceuticals.  14:363-369. 1999
1998 Synergistic therapy of breast cancer with Y90-chimeric L6 and paclitaxel in the xenografted mouse model: Development of a clinical protocol 1998
1998 Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenograftsClinical Cancer Research.  4:2483-2490. 1998
1998 A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapyJournal of Nuclear Medicine.  39:1223-1229. 1998
1998 Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. 1998
1998 Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study 1998
1998 Quantification of iodine-131 in tumors using a threshold based on image contrast 1998
1998 Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenograftsJournal of Nuclear Medicine.  39:842-849. 1998
1998 Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibodyCancer Biotherapy and Radiopharmaceuticals.  13:239-254. 1998
1998 Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphomaJournal of Clinical Oncology.  16:3246-3256. 1998
1998 Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibodyCancer Biotherapy and Radiopharmaceuticals.  13:1-12. 1998
1997 Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.Cancer.  80:2576-2582. 1997
1997 Imaging for improved prediction of myelotoxicity after radioimmunotherapy.Cancer.  80:2558-2566. 1997
1997 Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies.Cancer.  80:2553-2557. 1997
1997 Radioimmunotherapy for breast cancer using indium-11 l/yttrium-90 BrE-3: Results of a phase i clinical trialJournal of Nuclear Medicine.  38:1180-1185. 1997
1997 Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sourcesJournal of Nuclear Medicine.  38:1374-1378. 1997
1997 Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignanciesClinical Cancer Research.  3:1253-1260. 1997
1997 Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer 1997
1997 Practical determination of organ S values for individual patients for therapy.Nuclear Medicine and Biology.  24:447-449. 1997
1997 Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. 1997
1997 Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji)Clinical Cancer Research.  3:71-79. 1997
1997 Practical determination of organ S values for individual patients for therapyNuclear Medicine and Biology.  24:447-449. 1997
1997 Reproducibility of operator processing for radiation dosimetryNuclear Medicine and Biology.  24:77-83. 1997
1996 Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodiesJournal of Nuclear Medicine.  37:1970-1975. 1996
1996 Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy. 1996
1996 Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibratorJournal of Nuclear Medicine.  37:302-306. 1996
1996 A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapyNuclear Medicine and Biology.  23:525-532. 1996
1996 Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapyJournal of Nuclear Medicine.  37:146-150. 1996
1995 Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignanciesCancer Research.  55. 1995
1995 Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.Cancer Research.  55:5893s-5898s. 1995
1995 Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expressionCancer Research.  55. 1995
1995 Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.Cancer Research.  55:5837s-5841s. 1995
1995 Estimation of radiation absorbed doses to the red marrow in radioimmunotherapyClinical Nuclear Medicine.  20:117-125. 1995
1994 Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).Cancer.  73:1012-1022. 1994
1994 Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.Cancer.  73:1038-1048. 1994
1994 Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3)Cancer.  73:1012-1022. 1994
1994 Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131 i‐lym‐1 as a modelCancer.  73:1038-1048. 1994
1994 Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlungJournal of Nuclear Medicine.  35:1381-1389. 1994
1994 Quantitative bremsstrahlung imaging of yttrium-90 using a wienerMedical Physics.  21:1409-1417. 1994
1990 Photon correlation spectroscopy of the polarization signal from single muscle fibresJournal of Muscle Research and Cell Motility.  11:137-146. 1990
1989 Polarization states of diffracted light. Changes accompanying fiber activationBiophysical Journal.  56:595-605. 1989

Chapter

Year Title Altmetric
2010 Dosimetry for Targeted Radiotherapy.  473-506. 2010

Education And Training

  • Doctor of Philosophy, University of California System : Davis 1992
  • Full Name

  • Sui Shen